Figure 3From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinomaELISPOT kinetics of in vitro primed CAP-1 peptide specific-CD8+ T cell responses. T cell responses for all 14 patients at various time points on the trial are presented and stratified by treatment arm. Day 1 is first day of vaccination.Back to article page